ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/WA/6009-Nedlands-Hollywood-Private-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
12
trial(s) found.
NCT07612280
Haem
Phase 1 / Phase 2
Recruiting
Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis (
JBI-802-102
)
LSD1/HDAC6 inhibitor
Essential thrombocythaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
Myeloproliferative Neoplasm
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Hollywood Private Hospital
NCT07608848
Advanced
Phase 1
Recruiting
An Open-label, First-in-human, Exploratory Imaging Study of the
DOTA-STR-17126
Theranostic Pair [68Ga]Ga-
DOTA-STR-17126
and Low-dose [177Lu]Lu-
DOTA-STR-17126
in Patients With Advanced or Metastatic Cancer
177Lu-DOTA-STR-17126
cancer therapy
cancer therapy,GRPR-targeting
radioligand,GRPR-targeting
Breast cancer
Cancer
Prostate cancer
WA
6009 - Nedlands - Hollywood Private Hospital
NCT07546812
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (
GS-US-742-7757
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
cytotoxic chemotherapy
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - Hollywood Private Hospital
NCT07272642
Radonc
Phase 1
Not yet recruiting
A Phase 1, Multicenter Study of the Safety and Imaging of NTH-2403, a Lutetium-177 Radiolabeled Monoclonal Antibody Targeting the LRRC15 Epitope, in Participants With Locally Advanced or Metastatic Solid Tumors (
DUNP19
)
radioligand,LRRC15-targeting
Colorectal cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Triple-negative breast cancer
WA
6009 - Nedlands - Hollywood Private Hospital
NCT07259213
Radonc
Phase 1 / Phase 2
Recruiting
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-
RAD402
, a Radiolabeled Anti-Kallikrein-Related Peptidase 3 (KLK3) Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants With Castration-Resistant Prostate Cancer (CRPC)
radioconjugate,KLK3-targeting
Castrate-resistant prostate cancer
NSW
2500 - Wollongong - Wollongong Hospital
WA
6009 - Nedlands - Hollywood Private Hospital
NCT06940739
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel (
IOV-IL2-101
)
IL-2 fusion protein
autologous tumor-infiltrating lymphocytes therapy
Melanoma
NOT Uveal melanoma
Uveal melanoma
QLD
4120 - Greenslopes - Greenslopes Private Hospital
WA
6009 - Nedlands - Hollywood Private Hospital
NCT06841055
Advanced
Phase 2
Recruiting
A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC) (
BNT327-07
)
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - Hollywood Private Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06500273
Haem
Phase 2
Recruiting
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma (
ALPHA3
)
allogeneic CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
WA
6009 - Nedlands - Hollywood Private Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06372717
Haem
Phase 1
Recruiting
A Phase 1 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and in Combination With Azacitidine and in Combination With Azacitidine Plus Venetoclax in Adults With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB) (
AP30CP01
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
multikinase inhibitor,integrated stress response-targeting
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Hollywood Private Hospital
NCT05756322
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias (
LBS-007-CT01
)
CDC7 inhibitor
Leukaemia
NSW
2500 - Wollongong - Wollongong Private Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4217 - Benowa - Pindara Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Hollywood Private Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05417516
Radonc
Phase 3
Recruiting
A Randomized Trial of Five-Fraction Partial Breast Irradiation (RAPID2) (
OCOG-2022-RAPID2
)
Breast cancer
NSW
2010 - Darlinghurst - GenesisCare Sydney
2060 - Sydney - GenesisCare Mater
2220 - Hurstville - GenesisCare Hurstville
QLD
4215 - Southport - GenesisCare
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4655 - Urraween - GenesisCare Hervey Bay
4670 - Bundaberg - Bundaberg Hospital, Genesis Cancer Care
SA
5000 - South Australia - GenesisCare St Andrews Hospital
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Hollywood Private Hospital
6014 - Wembley - GenesisCare Wembley
6150 - Murdoch - GenesisCare Murdoch
NCT04614103
Advanced
Phase 2
Recruiting
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer (
IOV-LUN-202
)
autologous tumor infiltrating lymphocyte therapy
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
WA
6009 - Nedlands - Hollywood Private Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (11)
Not yet recruiting (1)
Recruitment Country and State
WA (12)
NSW (7)
QLD (6)
SA (4)
VIC (4)
TAS (2)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (4)
Phase 2 (4)
Phase 3 (1)
Trial Type
Advanced (5)
Haem (4)
Radonc (3)
Cancer Therapy Class
PD-1/PD-L1
17%
Bcl2
17%
DNA methyltransferase
17%
HDAC6
8%
LSD1
8%
GRPR
8%
CCR8
8%
PD-1
8%
VEGFR2
8%
LRRC15
8%
KLK3
8%
IL-2
8%
PD-L1
8%
VEGFA
8%
CD19
8%
ISR
8%
multikinase
8%
CDC7
8%
Facility
6009 - Nedlands - Hollywood Private Hospital (12)
3065 - Fitzroy - St Vincent's Hospital Melbourne (3)
3168 - Clayton - Monash Medical Centre (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
7000 - Hobart - Royal Hobart Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
2109 - North Ryde - Macquarie University Hospital (1)
6005 - West Perth - Perth Blood Institute (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2500 - Wollongong - Wollongong Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5000 - Adelaide - Cancer Research SA (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
2500 - Wollongong - Wollongong Private Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2010 - Darlinghurst - GenesisCare Sydney (1)
2060 - Sydney - GenesisCare Mater (1)
2220 - Hurstville - GenesisCare Hurstville (1)
4215 - Southport - GenesisCare (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
4655 - Urraween - GenesisCare Hervey Bay (1)
4670 - Bundaberg - Bundaberg Hospital, Genesis Cancer Care (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6014 - Wembley - GenesisCare Wembley (1)
6150 - Murdoch - GenesisCare Murdoch (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Thoracic cancer
Breast cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Myelodysplastic syndrome
Myeloproliferative neoplasm
Male genital cancers
Prostate cancer
Urogenital cancer
Gastrointestinal cancer
Leukaemia
Essential thrombocythaemia
Myelodysplastic/Myeloproliferative disease
Gastric adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Upper gastrointestinal cancer
cytotoxic chemotherapy
Breast adenocarcinoma
Colorectal cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Lower gastrointestinal cancer
Triple-negative breast cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Melanoma
Uveal melanoma
B-cell lymphoma
B-cell malignancy
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Acute myeloid leukaemia
Myeloid leukaemia
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy